^
    Back
    Association details:
    Biomarker:BAP1 I696T
    Cancer:Kidney Cancer
    Drug:sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Clin Genitourin Cancer
    Title:

    Mucinous tubular and spindle-cell carcinoma of the kidney: Clinical features, genomic profiles, and treatment outcomes.

    Published date:
    05/02/2020
    Excerpt:
    Four patients received systemic therapy with time to treatment failure ≤ 6 months across different agents with the exception of one patient with prolonged response on sunitinib (30.6 months)....The tumor of the patient who achieved long lived response on sunitinib harbored a total of 8 mutations including BAP1(I696T) missense mutation.
    DOI:
    10.1016/j.clgc.2019.04.006